A phase 1, randomized, double-blind, parallel, pharmacokinetic study of subcutaneous and intramuscular lanreotide in healthy volunteers.

Trial Profile

A phase 1, randomized, double-blind, parallel, pharmacokinetic study of subcutaneous and intramuscular lanreotide in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs Lanreotide (Primary) ; Lanreotide (Primary)
  • Indications Acromegaly
  • Focus Pharmacokinetics
  • Most Recent Events

    • 30 Sep 2016 According to an Ipsen Biopharmaceuticals media release, data from this study were presented at the annual symposium of the North American Neuroendocrine Tumor Society (NANETS).
    • 27 Jul 2015 New trial record
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top